AFFiRiS AG-Product Pipeline Review-2015

AFFiRiS AG-Product Pipeline Review-2015

  • Products Id :- GMDHC06957CDB
  • |
  • Pages: 36
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

AFFiRiS AG-Product Pipeline Review-2015


Global Markets Direct's, 'AFFiRiS AG-Product Pipeline Review-2015', provides an overview of the AFFiRiS AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AFFiRiS AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of AFFiRiS AG including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of AFFiRiS AG's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the AFFiRiS AG's pipeline products

Reasons To Buy

Evaluate AFFiRiS AG's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of AFFiRiS AG in its therapy areas of focus

Identify new drug targets and therapeutic classes in the AFFiRiS AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of AFFiRiS AG and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of AFFiRiS AG

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of AFFiRiS AG and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

AFFiRiS AG Snapshot 5

AFFiRiS AG Overview 5

Key Information 5

Key Facts 5

AFFiRiS AG-Research and Development Overview 6

Key Therapeutic Areas 6

AFFiRiS AG-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Out-Licensed Products 10

Out-Licensed Products/Combination Treatment Modalities 11

AFFiRiS AG-Pipeline Products Glance 12

AFFiRiS AG-Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

AFFiRiS AG-Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

AFFiRiS AG-Drug Profiles 16

AD-02 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

IMMAD-04 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

ATH-03 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

PD-01 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

PD-03 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

ATH-04 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Vaccine for Chronic Kidney Disease 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Vaccine for Type 2 Diabetes 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Vaccine to Target Angiotensin II for Cardiovascular Diseases 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Undisclosed Drug-1 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Undisclosed Drug-2 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

AFFiRiS AG-Pipeline Analysis 28

AFFiRiS AG-Pipeline Products by Target 28

AFFiRiS AG-Pipeline Products by Route of Administration 29

AFFiRiS AG-Pipeline Products by Molecule Type 30

AFFiRiS AG-Recent Pipeline Updates 31

AFFiRiS AG-Dormant Projects 33

AFFiRiS AG-Locations And Subsidiaries 34

Head Office 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Tables

AFFiRiS AG, Key Information 5

AFFiRiS AG, Key Facts 5

AFFiRiS AG-Pipeline by Indication, 2015 7

AFFiRiS AG-Pipeline by Stage of Development, 2015 8

AFFiRiS AG-Monotherapy Products in Pipeline, 2015 9

AFFiRiS AG-Out-Licensed Products in Pipeline, 2015 10

AFFiRiS AG-Out-Licensed Products/ Combination Treatment Modalities, 2015 11

AFFiRiS AG-Phase II, 2015 12

AFFiRiS AG-Phase I, 2015 13

AFFiRiS AG-Preclinical, 2015 14

AFFiRiS AG-Discovery, 2015 15

AFFiRiS AG-Pipeline by Target, 2015 28

AFFiRiS AG-Pipeline by Route of Administration, 2015 29

AFFiRiS AG-Pipeline by Molecule Type, 2015 30

AFFiRiS AG-Recent Pipeline Updates, 2015 31

AFFiRiS AG-Dormant Developmental Projects,2015 33

List of Figures

AFFiRiS AG-Pipeline by Top 10 Indication, 2015 7

AFFiRiS AG-Pipeline by Stage of Development, 2015 8

AFFiRiS AG-Monotherapy Products in Pipeline, 2015 9

AFFiRiS AG-Pipeline by Top 10 Target, 2015 28

AFFiRiS AG-Pipeline by Top 10 Route of Administration, 2015 29

AFFiRiS AG-Pipeline by Top 10 Molecule Type, 2015 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of AFFiRiS AG; AFFiRiS AG - Key Therapeutics; AFFiRiS AG - Pipeline Overview and Promising Molecules; AFFiRiS AG - News; AFFiRiS AG - Latest Updates; AFFiRiS AG - Pipeline; AFFiRiS AG - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 107220
Site License
USD 3000 INR 214440
Corporate User License
USD 4500 INR 321660



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]